Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to learn about ADRD prevalence within the Samoan population. Participants will be administered a series of cognitive assessments to determine cognitive status and a population-based prevalence of Mild Cognitive Impairment (MCI) and ADRD. Blood samples will also be collected from the participants for genetic and plasma biomarker analysis.


Clinical Trial Description

This study aims to do the following: Test ADRD knowledge, health literacy, research readiness and determine ADRD resilience and vulnerability factors, and cognitive status in a probability sample of 981 Samoans age 50+ using culturally adapted instruments in our probability sample. Conduct Gold Standard evaluations in our probability sample using the Uniform Data Set (UDSv3.0) from the National Institute on Aging (NIA) Alzheimer's Disease Research Center program to determine a population-based prevalence of MCI and ADRD for harmonization, data sharing, and comparison to other groups, and, Cross-validate Gold Standard dementia evaluations with genetic (i.e., ApoE) and plasma Amyloid-Tau-Neuronal Injury/Neurodegeneration (ATN) framework biomarkers in our probability sample and compare to information available for other racial/ethnic groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05924529
Study type Observational
Source American Samoa Community Cancer Coalition
Contact Siumu Fa'ai'uaso, BS
Phone 1-684-699-0110
Email sfaaiuaso@cancercoalition.as
Status Recruiting
Phase
Start date September 30, 2022
Completion date September 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03685240 - Fall Detection and Prevention for Memory Care Through Real-time Artificial Intelligence Applied to Video N/A